Extending the durability of response is the current focus in cancer immunotherapy with
immune checkpoint inhibitors (ICIs). However, factors like non-immunogenic tumor …

Chemokines are a class of small cytokines or signaling proteins that are secreted by cells.
Owing to their ability to induce directional chemotaxis of nearby responding cells, they are …

Immune checkpoint blockade (ICB)-based immunotherapy depends on functional tumour-
infiltrating lymphocytes (TILs), but essential cytokines are less understood. Here we uncover …

Resistance to immune checkpoint inhibitors (ICIs) is a major issue of the current era in
cancer immunotherapy. Immune evasion is a multi-factorial event, which occurs generally at …

The human immune system is an interaction network of biological processes, and its
dysfunction is closely associated with a wide array of diseases, such as cancer, infectious …

Neoantigens arising from somatic mutations are tumor specific and induce antitumor host T
cell responses. However, their sequences are individual specific and need to be identified …

Anti-PD-1 therapy targets intratumoral CD8+ T cells to promote clinical responses in cancer
patients. Recent evidence suggests an additional activity in the periphery, but the underlying …

Immune checkpoint inhibitors are groundbreaking resources for cancer therapy. However,
only a few patients with hepatocellular carcinoma (HCC) have shown positive responses to …

Pathogen‐mimicking nanoparticles have emerged at the forefront of vaccine delivery
technology, offering potent immune activation and excellent biocompatibility. Among these …

T cells are potent at eliminating pathogens and playing a crucial role in the adaptive immune
response. T cell receptor (TCR) convergence describes T cells that share identical TCRs …